Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16914421 | 1.00 | USP2 (0.43) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL19735966 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL16925009 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL28804271 | 0.82 | EPHX2 (0.40) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL5895323 | 0.79 | USP2 (0.47) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL24089120 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL20571915 | 0.79 | DDB1 (0.30) | DDB1CRBN | |
| SCHEMBL16925329 | 0.78 | USP2 (0.40) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL18392316 | 0.78 | USP2 (0.40) | USP2SMN1; SMN2EPHX2GPR119KDM4E | |
| SCHEMBL13342724 | 0.78 | USP30 (0.47) | GPR119KDM4EUSP30HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341124-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-09-20 | — | — | CN | disclosed |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11179397-B2 | Imidazopyrimidine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| CN-112625028-A | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107922388-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107787323-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020072656-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885 |
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | DPYD, KRAS, ABL1 | USP2 4022/4885SMN1; SMN2 356/4885EPHX2 3880/4885 |
| US-11179397-B2 | Imidazopyrimidine derivatives | DPYD, KRAS, ABL1 | USP2 4022/4885SMN1; SMN2 356/4885EPHX2 3880/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | USP2 1009/4885SMN1; SMN2 4080/4885EPHX2 2634/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885EPHX2 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.